



Our team



Dilu Mathew, PhD
Chief Executive Officer
Co-founder



Sachin Nair, PhD R&D Scientist



Pepijn Beekman, PhD
Chief Technology Officer
Co-founder



Bas Nooren Cleanroom Legend



Roel Schoondermark

Marketing Director


Board member




Alma Dudia, PhD
Assay Architect

The start of our journey

- Small (100nm) features
- Very sensitive
- Not very useful





Wanted .	Streptavidin-conjugated Alkaline phosphatase (SAV-ALP)
	Reporter anti-EpCAM (R-AE)
7	Capture anti-EpCAM (C-AE)
	p-aminophenyl phosphate (pAPP)
	p-aminophenol (pAP)
	p-quinone imine (pQI)
	Generic marker
	Epithelial cell adhesion molecule (EpCAM)
1	poly(ethylene glycol) diglycidyl ether (PEGDGE)
\	amino undecanethiol (AUT)
	Pt nanoelectrode

Prehistoric tests

Science lab vs. clinical practice

Clinicians: same tests as 40 years ago


 Unique combination of high tech and healthcare ecosystem

 Business as a vehicle to accelerate impact of science



Our secret

Platform Technology





Breakthrough nanotechnology



Attract target



Count targets one by one



Ónly count desired targets

Pioneers in Health Care


- Small powerful ecosystem (UT + hospitals)
- Ideation funding (10 vouchers, ~25% grant rate)
- Innovators meet clinicians
- Language

- UT + DZ: cancer
- UT+ MST + LabMicTA: COPD




COVID-19

- Labs open for corona research
- Low hanging fruit
- Market implementation
- Business case



Lab on a chip out of the lab















Rijksdienst voor Ondernemend Nederland

ECSENS





Reliable

- Ultimately sensitive
- Double redundant specificity
- Calibration-free
- Panel test


Simple

- Count bacteria/viruses one by one
- Robust clinical information
- Cost-effective

Point-of-care

- Real-time
- Decentral testing
- Central data analysis

Vicious circle of AMR




Using proven Labmicta ecosystem



- Business model validation
- Clinical validation
- Scientific collaborations
- Test panel design
- Next step: clinical verification study

- Major Dutch
 Microbiology lab
- All infection diagnostics in the region
- Central location (Hengelo, NL)



- 1 million inhabitants
- 600 points of care (GPs, hospitals, nursing homes)
- 10000 tests per day



Business model (Dutch market ____)

Product: Abacus

Customer, distributor, responsible party:

Central microbiology lab (medical specialist)

End user:

local GP, ER, OR, IC, nursing home, etc.



Cartridge

- One cartridge per patient
- Predetermined panel



Instrument

- ≥1 per POC
- Subscription model



Software

- Connecting caregiver, patient and microbiologist
- Subscription model

Insert Subtitle Text Here

A goal without a plan is just a wish

Area	2023	2024	2025	2026	2027	2028	2029
Clinical POC							
Abacus Product concept validation							
Proto alpha version development							
Clinical validation: proto alpha							
Design verification and pre production							
Regulatory certification							
Market launch							

Conclusion

PPP
Public demand
User feedback

Early stage funding
Crucial for innovation

Ecosystem
User partnership

Sepsis Zombie apocalypse

Occam Dx Make it count

